guest ::
| Home > Publications database > Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. > print |
| Home > Publications database > Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. > print |
| 001 | 143134 | ||
| 005 | 20240229105153.0 | ||
| 024 | 7 | _ | |a 10.18632/oncotarget.25594 |2 doi |
| 024 | 7 | _ | |a pmid:29983895 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC6033360 |2 pmc |
| 037 | _ | _ | |a DKFZ-2019-00743 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Regnery, Sebastian |0 P:(DE-He78)f4c0be14a7bb58948e5800ccdcbfe9bc |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Chemical exchange saturation transfer MRI serves as predictor of early progression in glioblastoma patients. |
| 260 | _ | _ | |a [S.l.] |c 2018 |b Impact Journals LLC |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1555505715_13471 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a To prospectively investigate chemical exchange saturation transfer (CEST) MRI in glioblastoma patients as predictor of early tumor progression after first-line treatment.Twenty previously untreated glioblastoma patients underwent CEST MRI employing a 7T whole-body scanner. Nuclear Overhauser effect (NOE) as well as amide proton transfer (APT) CEST signals were isolated using Lorentzian difference (LD) analysis and relaxation compensated by the apparent exchange-dependent relaxation rate (AREX) evaluation. Additionally, NOE-weighted asymmetric magnetic transfer ratio (MTRasym) and downfield-NOE-suppressed APT (dns-APT) were calculated. Patient response to consecutive treatment was determined according to the RANO criteria. Mean signal intensities of each contrast in the whole tumor area were compared between early-progressive and stable disease.Pre-treatment tumor signal intensity differed significantly regarding responsiveness to first-line therapy in NOE-LD (p = 0.0001), NOE-weighted MTRasym (p = 0.0186) and dns-APT (p = 0.0328) contrasts. Hence, significant prediction of early progression was possible employing NOE-LD (AUC = 0.98, p = 0.0005), NOE-weighted MTRasym (AUC = 0.83, p = 0.0166) and dns-APT (AUC = 0.80, p = 0.0318). The NOE-LD provided the highest sensitivity (91%) and specificity (100%).CEST derived contrasts, particularly NOE-weighted imaging and dns-APT, yielded significant predictors of early progression after fist-line therapy in glioblastoma. Therefore, CEST MRI might be considered as non-invasive tool for customization of treatment in the future. |
| 536 | _ | _ | |a 315 - Imaging and radiooncology (POF3-315) |0 G:(DE-HGF)POF3-315 |c POF3-315 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Adeberg, Sebastian |b 1 |
| 700 | 1 | _ | |a Dreher, Constantin |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Oberhollenzer, Johanna |0 P:(DE-He78)7c89f57d41cbe565e6154bf1997b9178 |b 3 |u dkfz |
| 700 | 1 | _ | |a Meissner, Jan-Eric |0 P:(DE-He78)65fe7a46247e2ac4b15f194631c56cd1 |b 4 |u dkfz |
| 700 | 1 | _ | |a Goerke, Steffen |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Windschuh, Johannes |0 P:(DE-He78)98b696ed60c17f4ddd0da9fdc20a2492 |b 6 |u dkfz |
| 700 | 1 | _ | |a Deike-Hofmann, Katerina |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Bickelhaupt, Sebastian |0 P:(DE-He78)d2d971750bce6217eb90fff9b01e61f9 |b 8 |u dkfz |
| 700 | 1 | _ | |a Zaiss, Moritz |b 9 |
| 700 | 1 | _ | |a Radbruch, Alexander |0 P:(DE-He78)77588f5b9413339755a66e739d316c7d |b 10 |u dkfz |
| 700 | 1 | _ | |a Bendszus, Martin |b 11 |
| 700 | 1 | _ | |a Wick, Wolfgang |0 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee |b 12 |u dkfz |
| 700 | 1 | _ | |a Unterberg, Andreas |b 13 |
| 700 | 1 | _ | |a Rieken, Stefan |b 14 |
| 700 | 1 | _ | |a Debus, Jürgen |b 15 |
| 700 | 1 | _ | |a Bachert, Peter |0 P:(DE-He78)29b2f01310f7022916255ddba2750f9b |b 16 |u dkfz |
| 700 | 1 | _ | |a Ladd, Mark |0 P:(DE-He78)022611a2317e4de40fd912e0a72293a8 |b 17 |u dkfz |
| 700 | 1 | _ | |a Schlemmer, Heinz-Peter |0 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |b 18 |u dkfz |
| 700 | 1 | _ | |a Paech, Daniel |0 P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc |b 19 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.18632/oncotarget.25594 |g Vol. 9, no. 47 |0 PERI:(DE-600)2560162-3 |n 47 |p 28772-28783 |t OncoTarget |v 9 |y 2018 |x 1949-2553 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:143134 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)f4c0be14a7bb58948e5800ccdcbfe9bc |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)7c89f57d41cbe565e6154bf1997b9178 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)65fe7a46247e2ac4b15f194631c56cd1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)98b696ed60c17f4ddd0da9fdc20a2492 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)d2d971750bce6217eb90fff9b01e61f9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)77588f5b9413339755a66e739d316c7d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)29b2f01310f7022916255ddba2750f9b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)022611a2317e4de40fd912e0a72293a8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)c6e31fb8f19e185e254174554a0cccfc |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-315 |2 G:(DE-HGF)POF3-300 |v Imaging and radiooncology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |
| 920 | 1 | _ | |0 I:(DE-He78)E010-20160331 |k E010 |l Radiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E020-20160331 |k E020 |l Medizinische Physik in der Radiologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)E012-20160331 |k E012 |l Neuroonkologische Bildgebung |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)G370-20160331 |k G370 |l KKE Neuroonkologie |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E010-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E012-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G370-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|